Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Reading Ashton
Institution:
University of Alabama at Birmingham
Observed institutions:
University of Alabama at Birmingham,
UAB Medicine
ORCID:
0000-0002-3708-758X
Observed ORCID:
0000-0002-3708-758X
OpenAlex ID:
A5026683992
Characterization of immune cell subtypes in three commonly used mouse strains reveals gender and strain-specific variations
2018
·
Jonathan A. Hensel
, Vinayak Khattar
, et al.
·
Laboratory Investigation
·
147
PDF
Recombinant AAV-CEA Tumor Vaccine in Combination with an Immune Adjuvant Breaks Tolerance and Provides Protective Immunity
2018
·
Jonathan A. Hensel
, Vinayak Khattar
, et al.
·
Molecular Therapy — Oncolytics
·
49
PDF
Location of tumor affects local and distant immune cell type and number
2017
·
Jonathan A. Hensel
, Vinayak Khattar
, et al.
·
Immunity Inflammation and Disease
·
17
PDF
RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity
2020
·
Hong Wang
, Reading Ashton
, et al.
·
Molecular Cancer Therapeutics
·
11
Systemic Checkpoint Blockade by PD-L1 Single-Chain Antibody Confers Potent Antitumor Immunity and Long-term Survival
2022
·
Hong Wang
, Vinayak Khattar
, et al.
·
Molecular Cancer Therapeutics
·
7
Mechanotransduction-Induced Gene Expression Reveals Activation of TGFβ/SKIL/TAZ Axis and Supports Invasive Phenotype in Triple-Negative Breast Cancer
2026
·
Rakesh K. Sharma
, Maranda Kramer
, et al.
·
International Journal of Molecular Sciences
·
1
PDF
Supplementary Figure from Systemic Checkpoint Blockade by PD-L1 Single-Chain Antibody Confers Potent Antitumor Immunity and Long-term Survival
2023
·
Hong Wang
, Vinayak Khattar
, et al.
Data from Systemic Checkpoint Blockade by PD-L1 Single-Chain Antibody Confers Potent Antitumor Immunity and Long-term Survival
2023
·
Hong Wang
, Vinayak Khattar
, et al.
Supplementary Figure from Systemic Checkpoint Blockade by PD-L1 Single-Chain Antibody Confers Potent Antitumor Immunity and Long-term Survival
2023
·
Hong Wang
, Vinayak Khattar
, et al.
Supplementary Data from RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity
2023
·
Hong Wang
, Reading Ashton
, et al.
Supplementary Methods from RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity
2023
·
Hong Wang
, Reading Ashton
, et al.
PDF
Supplementary Figures from RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity
2023
·
Hong Wang
, Reading Ashton
, et al.
PDF
Data from RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity
2023
·
Hong Wang
, Reading Ashton
, et al.
Supplementary Data from RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity
2023
·
Hong Wang
, Reading Ashton
, et al.
Data from RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity
2023
·
Hong Wang
, Reading Ashton
, et al.
Show more works
View as search
Works count:
15
Citation count:
232
H-index:
5
I10-index:
4
Year
Topic
Type